Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | KCNJ1 | P48048 | 12/20 | 0.40 |
| ▸ | GSK3B | P49841 | 4/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454396 | 1.00 | PDE10A (0.42) | PDE10AKCNJ1GSK3BDRD4ADRA1D | |
| SCHEMBL30454035 | 0.91 | PDE10A (0.42) | PDE10AKCNJ1GSK3BDRD4ADRA1D | |
| SCHEMBL30454441 | 0.91 | PDE10A (0.42) | PDE10AKCNJ1GSK3BDRD4ADRA1D | |
| SCHEMBL25355806 | 0.91 | PDE10A (0.42) | PDE10AKCNJ1GSK3BDRD4ADRA1D | |
| SCHEMBL25288287 | 0.91 | PDE10A (0.42) | PDE10AKCNJ1GSK3BDRD4ADRA1D | |
| SCHEMBL25355799 | 0.91 | PDE10A (0.42) | PDE10AKCNJ1GSK3BDRD4ADRA1D | |
| SCHEMBL30453129 | 0.89 | PDE10A (0.39) | PDE10AKCNJ1GSK3BDRD4 | |
| SCHEMBL25355357 | 0.89 | PDE10A (0.39) | PDE10AKCNJ1GSK3BDRD4 | |
| SCHEMBL25355352 | 0.89 | PDE10A (0.39) | PDE10AKCNJ1GSK3BDRD4 | |
| SCHEMBL25353543 | 0.88 | PDE10A (0.41) | PDE10AKCNJ1GSK3BDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| WO-2023122000-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | PDE10A 2248/4885KCNJ1 526/4885GSK3B 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.